These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11954205)

  • 1. Drug firms 'waging war' on the developing world.
    Munro R
    Nurs Times; 2001 Feb 22-28; 97(8):10. PubMed ID: 11954205
    [No Abstract]   [Full Text] [Related]  

  • 2. Health priorities gain patent reprieve for developing countries.
    Cherry M
    Nature; 2001 Nov; 414(6862):385. PubMed ID: 11719767
    [No Abstract]   [Full Text] [Related]  

  • 3. Reforming Canada's Access to Medicines Regime.
    Elliott R
    CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
    [No Abstract]   [Full Text] [Related]  

  • 4. Gilead's Viread international access program.
    Huff B
    GMHC Treat Issues; 2003 May; 17(5):11. PubMed ID: 12846177
    [No Abstract]   [Full Text] [Related]  

  • 5. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM
    Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
    [No Abstract]   [Full Text] [Related]  

  • 6. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 7. Patents and access to drugs in developing countries: an ethical analysis.
    Sterckx S
    Dev World Bioeth; 2004 May; 4(1):58-75. PubMed ID: 15086374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The WTO's balancing act.
    Novak K
    J Clin Invest; 2003 Nov; 112(9):1269-73. PubMed ID: 14597749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patent laws. Report urges leeway for developing world.
    Couzin J; Bagla P
    Science; 2002 Sep; 297(5588):1791. PubMed ID: 12228696
    [No Abstract]   [Full Text] [Related]  

  • 10. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
    Sykes AO
    Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug research. WHO panel weighs radical ideas.
    Enserink M
    Science; 2006 Dec; 314(5804):1373. PubMed ID: 17138875
    [No Abstract]   [Full Text] [Related]  

  • 12. The GO License: only part of the solution.
    Batson A; Milstien JB
    Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs are scarce as mix of programs aims to ease access.
    Brower V
    J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
    [No Abstract]   [Full Text] [Related]  

  • 14. More drugs, less protection.
    Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
    [No Abstract]   [Full Text] [Related]  

  • 15. The Health Impact Fund.
    Light DW
    Lancet; 2010 Mar; 375(9718):893. PubMed ID: 20226984
    [No Abstract]   [Full Text] [Related]  

  • 16. In wake of 9/11, drug-patent rules change.
    Cassels A
    CMAJ; 2002 Feb; 166(3):366. PubMed ID: 11868652
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA notifications. Tentative approval of India-made zidovudine.
    AIDS Alert; 2005 Sep; 20(9):108. PubMed ID: 16206404
    [No Abstract]   [Full Text] [Related]  

  • 18. Reinventing an industry.
    Mandavilli A
    Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
    [No Abstract]   [Full Text] [Related]  

  • 19. Indian biogenerics industry emerges.
    Jayaraman KS
    Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract]   [Full Text] [Related]  

  • 20. World CAB meets with Gilead.
    Huff B
    GMHC Treat Issues; 2006; 20(4-7):6-8. PubMed ID: 17228449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.